Aanesthetic Agents for Day Surgery - NIHR Health Technology ...

More documents

Recommendations

Info

164 Appendix 8 TABLE 70 contd Characteristics of cost or economic comparisons of anaesthetic agents Authors Year of Country of Type of Alternatives compared No. of publication study study * subjects Smith et al. 221 Song et al. 126 Sun et al. 222 1999 Multicentre: Cost Propofol TIVA 72 Belgium, Propofol/sevoflurane 70 France,The Sevoflurane/sevoflurane 69 Netherlands, Thiopentone/isoflurane 22 UK 1998 USA Effectiveness Fast tracking vs standard care 120 1999 USA Cost– Methohexitone/sevoflurane 30 consequences Methohexitone/desflurane 30 Propofol/sevoflurane 30 Propofol/desflurane 30 Tang et al. 129 1999 USA Economics Propofol TIVA 35 Propofol/sevoflurane 34 Sevoflurane/sevoflurane 35 Wagner and 1995 USA Cost Propofol induction 103 O’Hara 223 Thiopentone induction 140 Wagner and 1997 USA Economic Sevoflurane 25 O’Hara 224 Isoflurane 22 * Defined by author
TABLE 71 Quality of cost or economic comparisons of anaesthetic agents © Queen’s Printer and Controller of HMSO 2002. All rights reserved. Health Technology Assessment 2002; Vol. 6: No. 30 Study Study design Resources measured and costed Source of costs Results Data collection Economic checklist Alhashemi et al., Source: RCT Study design: INAD Anaesthetic and drugs, Not stated Costs 1997, 29 Canada nursing time Inhalational: Randomisation: Effectiveness data: US $36.4 ± 5.3 * CGRNT INAD Balanced: Blind: single Outcome data: NA US $66.5 ± 11.7 * Power estimate: Cost data: UNACC TIVA: US $86.0 ± 20.6 * NK Analysis: INAD p < 0.05, different to Inclusion/ each other exclusion criteria: Sensitivity analysis: 11 no Effectiveness * Recruitment rates: NK Representative sample: NK Comparable groups: yes No differences Churnside et al., Audit Study design:AD Consumables List prices Detailed median (range) 1996, 23 UK costs estimated for day- Cost data:ACCEPT Equipment Salary costs surgery procedures and prespecified anaesthetic Analysis: INAD Labour Literature regimen Sensitivity analysis: Overheads no Dexter and Tinker, Source: Study design: INAD Total charges per Charges Eliminating adverse 1995, 40 USA descriptive, inpatient episode, anaesthesia outcomes retrospective Effectiveness data: excludes physician fees decreases total costs chart review, INAD by 0–2% no controls Outcome data: INAD Cost data: INAD Analysis: INAD Appendix 9 Quality of cost or economic comparisons of anaesthetic agents continued 165
Page 1 and 2:
Which anaesthetic agents are costef
Page 3:
Which anaesthetic agents are costef
Page 6 and 7:
NHS R&D HTA Programme The NHS R&D H
Page 8 and 9:
Contents Appendix 6 Adult patient-b
Page 11 and 12:
Background The aim of the project w
Page 13:
• The incidence of PONV was low d
Page 16 and 17:
2 Introduction dizziness or disorie
Page 18 and 19:
4 Introduction a reduced incidence
Page 20 and 21:
6 Introduction willingness to pay f
Page 22 and 23:
8 Literature review included in the
Page 24 and 25:
10 Literature review TABLE 1 Compar
Page 26 and 27:
12 Literature review intermediate a
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
18 Literature review Patient-based
Page 34 and 35:
20 Literature review TABLE 5 contd
Page 36 and 37:
22 Literature review No studies fol
Page 38 and 39:
24 Literature review (30%) and meth
Page 40 and 41:
26 Literature review • There are
Page 42 and 43:
28 National survey of anaesthetic p
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
36 Economic evaluation methods (inc
Page 52 and 53:
38 Economic evaluation methods The
Page 54 and 55:
40 Economic evaluation methods Tabl
Page 56 and 57:
42 Economic evaluation methods simi
Page 58 and 59:
44 Economic evaluation methods Prob
Page 61 and 62:
Recruitment to the CESA RCT The stu
Page 63 and 64:
Clinical outcome data PONV by anaes
Page 65 and 66:
The findings from the logistic regr
Page 67 and 68:
TABLE 29 The length of stay and pri
Page 69 and 70:
140 120 100 80 60 40 20 0 No. of pa
Page 71 and 72:
250 200 150 100 50 0 No. of patient
Page 73 and 74:
TABLE 37 Deterministic sensitivity
Page 75 and 76:
20 15 10 5 0 -5 Difference in varia
Page 77 and 78:
Patient admitted for day surgery an
Page 79 and 80:
500 400 300 200 100 0 -100 -200 -30
Page 81 and 82:
Recruitment to the CESA RCT The stu
Page 83 and 84:
TABLE 49 The occurrence of any PONV
Page 85 and 86:
60 50 40 30 20 10 0 No. of patients
Page 87 and 88:
a scale effect for scenario A, but
Page 89 and 90:
The mean CVs for avoidance of PONV
Page 91 and 92:
1.80 The new variable cost and tota
Page 93 and 94:
100 90 80 70 60 50 40 30 20 10 0 Su
Page 95 and 96:
The structure and content of this d
Page 97 and 98:
nurses to have an in-depth knowledg
Page 99 and 100:
agent used (see appendix 18). It wa
Page 101 and 102:
Furthermore, anaesthetists operate
Page 103 and 104:
The CESA project was designed to as
Page 105:
practice, such as the use of midazo
Page 109 and 110:
1. Royal College of Surgeons of Eng
Page 111 and 112:
60. Cheng KI, Chu KS, Fang YR, Su K
Page 113 and 114:
112. Raeder J, Gupta A, Pedersen FM
Page 115 and 116:
162. Viitanen H, Baer G, Annila P.
Page 117 and 118:
220. Rosenberg KM, Bridge P, Brown
Page 119 and 120:
The range of databases interrogated
Page 121:
24. preferen$.mp. [mp=title, abstra
Page 124 and 125:
110 Appendix 2 TABLE 65 contd Summa
Page 126 and 127:
112 Appendix 3 Quality assessment o
Page 128 and 129: 114 Appendix 4 TABLE 66 contd Summa
Page 173 and 174: TABLE 69 Summary of paediatric pati
Page 175 and 176: TABLE 69 contd Summary of paediatri
Page 177: TABLE 70 Characteristics of cost or
Page 181 and 182: TABLE 71 contd Quality of cost or e
Page 189 and 190: Abbott J, Abbott P. Psychological a
Page 191 and 192: Hall JE, Stewart JIM, Harmer M. Sin
Page 193: Struys M, Versichelen L, Thas O, He
Page 196 and 197: 182 Appendix 11
Page 205 and 206: The aim of this study was to develo
Page 207 and 208: anaesthetics in day surgery, using
Page 209: © Queen’s Printer and Controller
Page 213 and 214: Background The empirical study quan
Page 215 and 216: Satisfaction with care Nearly all (
Page 217 and 218: TABLE 76 Reason given for preferenc
Page 219 and 220: TABLE 79 Comparisons with previous
Page 221 and 222: TABLE 80 Reason given for preferenc
Page 223 and 224: TABLE 81 Reason given for willingne
Page 225 and 226: Background Variable costs account f
Page 227 and 228: TABLE 85 Unit costs for the purchas
Page 229 and 230:
Background The empirical study requ
Page 231 and 232:
Ethical approval This was covered b
Page 233 and 234:
20 15 10 5 0 -5 -10 -15 True weight
Page 235:
15 10 5 0 -5 -10 True weight - Dion
Page 238 and 239:
224 Appendix 19 • patients aged o
Page 241 and 242:
All staff unit costs were for the y
Page 243:
Background Fixed costs account for
Page 246 and 247:
232 Appendix 22 March, Tuesday 15 A
Page 248 and 249:
234 Appendix 23 TABLE 96 Reasons fo
Page 251 and 252:
Patients were coded using the OPCS
Page 253 and 254:
Q03.4 punch biopsy of cervix Q03.5
Page 255 and 256:
This section displays the associati
Page 257 and 258:
given in Table 103 confirm the age
Page 259:
TABLE 107 Occurrence of PONV by dur
Page 262 and 263:
248 Appendix 27 TABLE 113 Frequency
Page 265 and 266:
This section displays the associati
Page 267 and 268:
The adverse events observed in the
Page 269 and 270:
262 Health Technology Assessment Pr
Page 271:
264 Health Technology Assessment Pr
show all

Aanesthetic Agents for Day Surgery - NIHR Health Technology ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?